Commodore Capital LP Has $25.01 Million Stock Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Commodore Capital LP lowered its position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 64.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,000,000 shares of the company’s stock after selling 1,850,000 shares during the quarter. Centessa Pharmaceuticals accounts for approximately 1.7% of Commodore Capital LP’s investment portfolio, making the stock its 24th largest position. Commodore Capital LP owned approximately 0.74% of Centessa Pharmaceuticals worth $25,010,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in CNTA. TD Waterhouse Canada Inc. acquired a new stake in Centessa Pharmaceuticals during the 4th quarter worth approximately $25,000. Caitong International Asset Management Co. Ltd acquired a new position in Centessa Pharmaceuticals in the 4th quarter valued at approximately $36,000. T. Rowe Price Investment Management Inc. raised its stake in shares of Centessa Pharmaceuticals by 7,580.0% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock valued at $39,000 after acquiring an additional 1,516 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Centessa Pharmaceuticals by 42.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock worth $85,000 after purchasing an additional 1,008 shares during the period. Finally, Knott David M Jr bought a new stake in shares of Centessa Pharmaceuticals in the fourth quarter worth $100,000. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Stock Performance

Shares of Centessa Pharmaceuticals stock opened at $39.87 on Thursday. The business has a 50-day moving average price of $39.65 and a two-hundred day moving average price of $31.11. Centessa Pharmaceuticals PLC Sponsored ADR has a 1-year low of $12.30 and a 1-year high of $40.26. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.23. The company has a market cap of $6.17 billion, a P/E ratio of -22.27 and a beta of 1.11.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Tuesday, May 5th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.14). As a group, analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current year.

Insider Transactions at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Karen M. Anderson sold 41,076 shares of the stock in a transaction that occurred on Thursday, March 26th. The stock was sold at an average price of $30.12, for a total transaction of $1,237,209.12. Following the transaction, the insider directly owned 62,085 shares in the company, valued at approximately $1,870,000.20. This represents a 39.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.09% of the company’s stock.

Analyst Ratings Changes

CNTA has been the subject of several analyst reports. Lifesci Capital lowered Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 1st. Wolfe Research lowered Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research report on Tuesday, March 31st. Guggenheim downgraded Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 2nd. Needham & Company LLC lowered Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Finally, Wells Fargo & Company cut Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and upped their target price for the company from $35.00 to $42.00 in a report on Monday, April 20th. Four investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $41.33.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical?stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision?making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.